Achillion Aiming For Best-In-Class Protease Inhibitor, Working On Home-Grown Hep C Cocktail
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
While hepatitis C drug developers ponder the safety and tolerability issues likely to arise when direct-acting antivirals are combined in cocktails against the virus, Achillion Pharmaceuticals, Inc., a small company in New Haven, CT, is working on a portfolio of candidates it says not only combine safely, they work better in combination.
You may also be interested in...
Gilead/Bristol Hep C Combo Gets High Marks At EASL, But Its Future Is In Doubt
All eyes are on Gilead Sciences following the news it may not continue development of GS-7977 alongside Bristol-Myers Squibb’s daclatasvir, though the all-oral pairing produced impressive data in Phase II.
Hepatitis C Opportunities Light Up Infectious Disease Partnering Landscape
"Without question, hepatitis C is the number one exciting area in infectious diseases," insists Paul Zhang, a principal in the health care advisory group Easton Associates, LLC.
Achillion HCV Candidate Shows Promising Phase I Results In Once-Daily Dosing
Biotech says that latest data on its protease inhibitor ACH-1625 enhances its position in negotiating partnerships for the compound.